Physician profile
Andrew E Bourne
NPI 1346462702
$5,633.09
in general payments reported to CMS, 2019-2025
32 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,317 · 2020: $234 · 2021: $452 · 2022: $359 · 2023: $241 · 2024: $315 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,905.09 | 2019-2025 | Porges Coloplast |
| Neotract INC. | $1,257.54 | 2019-2020 | |
| Abbvie INC. | $267.47 | 2019-2025 | Botox |
| Axonics, INC. | $261.83 | 2020-2023 | Axonics |
| Astellas Pharma US INC | $247.81 | 2019-2023 | Myrbetriq, Xtandi, Veozah |
| Histosonics, INC. | $170.62 | 2025 | |
| Calyxo, INC. | $167.73 | 2025 | Cvac Aspiration System |
| Boston Scientific Corporation | $162.54 | 2019-2025 | Spaceoar Vue System - 10ml, Axonics, Rezum Generator |
| Procept Biorobotics Corporation | $140.00 | 2021 | |
| Medtronic, INC. | $105.90 | 2021-2023 | Interstim |
| 180 Medical, INC. | $103.89 | 2019-2024 | Gentlecath Glide, Gentlecath |
| Pfizer INC. | $102.01 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $82.87 | 2019-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $66.46 | 2019-2024 | |
| Janssen Biotech, INC. | $62.14 | 2019-2024 | Erleada, Akeega |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $57.78 | 2022-2025 | Jelmyto |
| Amgen INC. | $56.38 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $53.25 | 2020-2023 | Xiaflex, Aveed |
| Tolmar Pharmaceuticals, INC. | $48.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $35.16 | 2024-2025 | Keytruda |
| Telix Pharmaceuticals | $35.11 | 2024-2025 | Illuccix |
| Teleflex LLC | $33.31 | 2023 | Urolift |
| Novartis Pharmaceuticals Corporation | $29.76 | 2023 | |
| Dornier Medtech America, INC | $28.68 | 2020 | |
| Endo USA, INC. | $28.65 | 2024 | Xiaflex |
| Ferring Pharmaceuticals INC. | $27.77 | 2019 | |
| Sumitomo Pharma America, INC. | $19.89 | 2025 | Gemtesa |
| Abbott Laboratories | $17.13 | 2022 | |
| Photocure INC | $15.93 | 2022 | |
| Tolmar, INC. | $15.30 | 2024 | |
| Olympus America INC. | $14.55 | 2024 | Itind System |
| Karl Storz Endoscopy-America | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.